Clinical trial · Observational
Application of Ultrasound Radiomics in Ultrasound Fusion Targeted Prostate Biopsy
NCT05761912CI-TRIAL-00101383active not recruitingClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
To predict prostate cancer by ultrasound radiomics in ultrasound fusion prostate targeted biopsy.
Conditions
Conditions (3)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Prostate Cancer | Malignant Prostate Neoplasm | CURATED_EXACT | 0.92 |
| Radiomics | — | UNRESOLVED | — |
| Ultrasound | — | UNRESOLVED | — |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Targeted biopsy | Diagnostic Test | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- label
- Ultrasound fusion targeted biopsy
- description
- Prostate ultrasound had abnormal echo and radiomics analysis showed high scores
- interventionNames
- Diagnostic Test: Targeted biopsy
- label
- Systematic biopsy
- description
- Patients meeting the indications for prostate biopsy
Primary outcomes (4)
- measure
- Positive rate of ultrasound radiomics fusion targeted biopsy
- timeFrame
- Up to seventh day when the pathological results were obtained after the targeted biopsy
- description
- Positive rate of ultrasound radiomics fusion targeted biopsy
- measure
- Positive rate of systematic biopsy
Eligibility
Eligibility (as posted)
- Sex
- Male
- Minimum age
- 55 Years
Show eligibility criteria text
Inclusion Criteria: 1. Age ≥55 years old. 2. Patients had tPSA/fPSA within 1 month before biopsy. 3. Patients had any of the following indications for prostate biopsy: * Suspicious prostate nodules were found by digital rectal examination * Suspicious lesions were detected by B-ultrasound or MRI * PSA\>10ng/ml * PSA 4-10ng/ml, with abnormal f/tPSA and/or PSAD values Exclusion Criteria: 1. malignant tumors other than prostate adenocarcinoma indicated by pathology. 2. Combined with other malignant tumors (such as rectal cancer, bladder cancer, testicular cancer, etc.) that may affect the imaging findings of transrectal ultrasound or mpMRI. 3. Other conditions that would preclude needle biopsy: cachexia, decompensation of organ function, hemorrhagic diseases, local infection, etc
References
Publications (0)
Data not yet available
No reference posted for this study.